UT Southwestern Medical Center is collaborating with Pfizer Inc. to develop RNA enhanced delivery technologies for genetic medicine therapies through the Dallas-based medical center’s Program in Genetic Drug Engineering.

Carlos L. Arteaga, M.D., Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, and David Mangelsdorf, Ph.D., Chair and Professor of Pharmacology and Professor of Biochemistry, have been elected to the National Academy

When Haley and Zachary Sanders had their first baby, Rowan, and learned she had multiple heart defects, they were shattered. They never imagined technology borrowed from video games would help save their baby’s life.

An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target.

Starting this fall, the biggest public high schools in Texas are required to report all sports concussions to a central database as part of one of the nation’s largest statewide endeavors to track brain injuries in youth athletics.

James J. Collins III, Ph.D., Associate Professor of Pharmacology at UT Southwestern Medical Center who leads groundbreaking research into the parasitic disease schistosomiasis, has been named a Howard Hughes Medical Institute (HHMI) Investigator.

The hormone LEAP2, which naturally blocks the “hunger” hormone ghrelin, is elevated in people with obesity, especially after eating – raising hopes for a treatment that could one day more effectively reduce appetite and, hence, obesity.

Dr. Joseph Takahashi, noted for discovering the first gene controlling biological clocks in mammals, addressed the topic at the Society for Neuroscience annual meeting where he was awarded the Gruber Neuroscience Prize for his pioneering work in circadian rhythms.

A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a single copy of the most common genetic mutation for the disease.

A new blood test for protein biomarkers could identify high risk heart patients.